-transparent.png){kind=logo}
A variety of dopaminergic ligands were evaluated for their ability to alter glucose transport in PC12 cells. Certain antipsychotic drugs which targeted D2 dopamine receptors, such as pimozide, fluphenazine and chlorpromazine, inhibited glucose uptake (with IC50's in the range of 2-40 microM). By contrast, haloperidol and sulpiride (also D2 antagonists) showed marginal activity. The atypical antipsychotic drug, clozapine (a D4 antagonist), also effectively inhibited glucose transport by the cells. Ligands specific for D1 receptors did not interfere with glucose uptake. Time course studies revealed that a short incubation with the drugs (1-5 min) was sufficient to block glucose transport. These findings may have implications for the adverse effects of these drugs and for the interpretation of imaging studies of brain glucose metabolism in patients on antipsychotic medications.
D S Dwyer, and
Y Liu, and
R J Bradley
August 2000,
Brain research bulletin,
D S Dwyer, and
Y Liu, and
R J Bradley
April 1991,
Neurochemical research,
D S Dwyer, and
Y Liu, and
R J Bradley
January 2023,
Methods in molecular biology (Clifton, N.J.),
D S Dwyer, and
Y Liu, and
R J Bradley
March 2006,
Phytotherapy research : PTR,
D S Dwyer, and
Y Liu, and
R J Bradley
January 2015,
Neuro-Signals,
D S Dwyer, and
Y Liu, and
R J Bradley
February 1995,
Brain research,
D S Dwyer, and
Y Liu, and
R J Bradley
April 1985,
The Journal of biological chemistry,
D S Dwyer, and
Y Liu, and
R J Bradley
January 1996,
Life sciences,
D S Dwyer, and
Y Liu, and
R J Bradley
May 2006,
Proteomics,
D S Dwyer, and
Y Liu, and
R J Bradley
September 1989,
FEBS letters,
